Christian W. Scholz

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

Agnieszka Korfel, Thomas Elter, E. Thiel et al. · Haematologica · 2012 · 138 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study

Peter Thuss‐Patience, Albrecht Kretzschmar, Michael Repp et al. · Journal of Clinical Oncology · 2005 · 114 citations · Full text

Medicine, Oncology, Pharmacology +15

⁹⁰Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial

Christian W. Scholz, Werner Linkesch, Ola Lindén et al. · Journal of Clinical Oncology · 2012 · 108 citations · Full text

Medicine, Hematology, Oncology +16

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Michael Thomas, Santiago Ponce-Aix, Alejandro Navarro et al. · Annals of Oncology · 2018 · 81 citations · Full text

Medicine, Oncology, Pharmacology +15